Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. The sensitiviy of gefitinib in various NSCLC cell lines from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
  1. Home
  2. Publications
  3. The sensitiviy of gefitinib in various NSCLC cell lines from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer

The sensitiviy of gefitinib in various NSCLC cell lines from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer

Authors:
  • JJJi-Young Jang
    Ji-Young Jang
  • YKYong-Goo Kim
    Yong-Goo Kim
  • SNSoo Jeong Nam
    Soo Jeong Nam
  • BKBhumsuk Keam
    Bhumsuk Keam
  • TKTae Min Kim
    Tae Min Kim
  • YJYoon Kyung Jeon
    Yoon Kyung Jeon
  • CKChul Woo Kim
    Chul Woo Kim

Open Access
Publisher website
Google Scholar
  • 3 April 2023
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1535-7163.22501185
Abstract
No abstract available
Keywords
  • VIABILITY ASSAY
  • GROWTH INHIBITION
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.